NO20064328L - Isoquinolinderivater og fremgangsmater for anvendelse derav - Google Patents
Isoquinolinderivater og fremgangsmater for anvendelse deravInfo
- Publication number
- NO20064328L NO20064328L NO20064328A NO20064328A NO20064328L NO 20064328 L NO20064328 L NO 20064328L NO 20064328 A NO20064328 A NO 20064328A NO 20064328 A NO20064328 A NO 20064328A NO 20064328 L NO20064328 L NO 20064328L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- methods
- cardiovascular disease
- isoquinoline
- isoquinoline derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54789904P | 2004-02-26 | 2004-02-26 | |
PCT/US2005/006243 WO2005082368A1 (en) | 2004-02-26 | 2005-02-25 | Isoquinoline derivatives and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064328L true NO20064328L (no) | 2006-10-26 |
Family
ID=34910959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064328A NO20064328L (no) | 2004-02-26 | 2006-09-25 | Isoquinolinderivater og fremgangsmater for anvendelse derav |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050228007A1 (es) |
EP (2) | EP2033645A1 (es) |
JP (1) | JP2007527872A (es) |
KR (1) | KR20060125909A (es) |
CN (1) | CN1964716A (es) |
AU (1) | AU2005216978A1 (es) |
BR (1) | BRPI0508233A (es) |
CA (1) | CA2557547A1 (es) |
EA (1) | EA200601558A1 (es) |
IL (1) | IL177650A0 (es) |
MX (1) | MXPA06009701A (es) |
NO (1) | NO20064328L (es) |
WO (1) | WO2005082368A1 (es) |
ZA (1) | ZA200607913B (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956035B2 (en) * | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
US7217709B2 (en) * | 2003-02-28 | 2007-05-15 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
JP2007525526A (ja) * | 2004-02-26 | 2007-09-06 | イノテック ファーマシューティカルズ コーポレイション | 四環系ラクタム誘導体およびその使用 |
JP2008503466A (ja) * | 2004-06-16 | 2008-02-07 | イノテック ファーマシューティカルズ コーポレイション | 勃起不全または尿失禁を治療または予防する方法 |
WO2006093677A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic sulfonamide compounds and methods of use thereof |
AU2006219022A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Isoqunoline Compounds and methods of use thereof |
WO2006093667A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic amino and carboxamido compounds and methods of use thereof |
BRPI0615096A2 (pt) * | 2005-08-24 | 2009-07-14 | Inotek Pharmaceuticals Corp | análogos de indenoisoquinolinona e métodos de uso dos mesmos |
JP5271897B2 (ja) | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体 |
EP2336120B1 (en) | 2007-01-10 | 2014-07-16 | MSD Italia S.r.l. | Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
AU2008221358A1 (en) * | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
GB0716532D0 (en) | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US8642582B2 (en) | 2008-12-05 | 2014-02-04 | Merck Sharp & Dohme Corp. | Morpholinone compounds as factor IXa inhibitors |
BR112014031785A2 (pt) * | 2012-06-20 | 2017-06-27 | Hoffmann La Roche | composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção |
KR102087017B1 (ko) * | 2012-10-11 | 2020-03-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
BR112017027690A2 (pt) | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco |
EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
EP3630813A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
CN117838880A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
EP3677589A4 (en) | 2017-08-31 | 2021-04-21 | Daiichi Sankyo Company, Limited | IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE |
CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
US20190365735A1 (en) * | 2018-05-31 | 2019-12-05 | Campbell Frederick Mcauley | Compositions and methods for treating varicose veins |
CN111777613A (zh) * | 2019-04-03 | 2020-10-16 | 中国药科大学 | 嘧啶二酮并吲哚和吡啶酮并吲哚类化合物的制备及用途 |
CN113480520B (zh) * | 2021-08-16 | 2022-05-13 | 吉林大学 | 一种异喹啉-1,3(2h,4h)-二酮衍生物及其应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) * | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
IT1054655B (it) * | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
US4263304A (en) * | 1978-06-05 | 1981-04-21 | Sumitomo Chemical Company, Limited | 7 H-indolo[2,3-c]isoquinolines |
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
GB8828806D0 (en) * | 1988-12-09 | 1989-01-18 | Beecham Group Plc | Novel compounds |
US5028079A (en) * | 1989-10-17 | 1991-07-02 | J. M. Huber Corporation | Non-crushing wellhead |
US5260316A (en) * | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
SK278794B6 (sk) | 1991-08-29 | 1998-03-04 | V�Fb | 2-hydroxyetylaminosubstituované deriváty 5,11-diox |
US5597831A (en) * | 1991-08-29 | 1997-01-28 | Vufb A.S | 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents |
AU678982B2 (en) * | 1992-08-14 | 1997-06-19 | Commonwealth Scientific And Industrial Research Organisation | Insect viruses and their uses in protecting plants |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
TW440562B (en) * | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
US6250301B1 (en) | 1997-08-28 | 2001-06-26 | Hortal Harm B.V. | Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix |
US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
US6346536B1 (en) * | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
AU9297998A (en) | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
WO1999059975A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
JP2002523378A (ja) * | 1998-08-24 | 2002-07-30 | マキシム ファーマシューティカルズ インコーポレイテッド | H2−レセプターアゴニストおよび他のt−細胞活性化薬剤を用いたt−細胞(cd4+およびcd8+)の活性化および保護 |
DE69940523D1 (de) * | 1998-10-14 | 2009-04-16 | Purdue Research Foundation | Neue indenoisoquinoline als antineoplastische mittel |
US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
ATE261963T1 (de) | 1999-01-11 | 2004-04-15 | Agouron Pharma | Tricyclische inhibitoren von poly(adp-ribose) polymerasen |
US6346535B1 (en) * | 1999-01-29 | 2002-02-12 | American Cyanamid Company | Fungicidal mixtures |
EP1200074A2 (en) * | 1999-07-16 | 2002-05-02 | Maxim Pharmaceuticals, Inc. | Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US6476048B1 (en) * | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6277990B1 (en) * | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
US20030096833A1 (en) * | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
US6956035B2 (en) * | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US7217709B2 (en) * | 2003-02-28 | 2007-05-15 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
JP2007525526A (ja) * | 2004-02-26 | 2007-09-06 | イノテック ファーマシューティカルズ コーポレイション | 四環系ラクタム誘導体およびその使用 |
JP2008503466A (ja) * | 2004-06-16 | 2008-02-07 | イノテック ファーマシューティカルズ コーポレイション | 勃起不全または尿失禁を治療または予防する方法 |
WO2006039545A2 (en) * | 2004-09-30 | 2006-04-13 | Maxim Pharmaceuticals, Inc. | Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
WO2006093667A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic amino and carboxamido compounds and methods of use thereof |
AU2006219022A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Isoqunoline Compounds and methods of use thereof |
WO2006093677A1 (en) * | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic sulfonamide compounds and methods of use thereof |
BRPI0615096A2 (pt) * | 2005-08-24 | 2009-07-14 | Inotek Pharmaceuticals Corp | análogos de indenoisoquinolinona e métodos de uso dos mesmos |
-
2005
- 2005-02-25 EP EP08015611A patent/EP2033645A1/en not_active Withdrawn
- 2005-02-25 BR BRPI0508233-1A patent/BRPI0508233A/pt not_active IP Right Cessation
- 2005-02-25 US US11/066,824 patent/US20050228007A1/en not_active Abandoned
- 2005-02-25 JP JP2007501043A patent/JP2007527872A/ja not_active Withdrawn
- 2005-02-25 EP EP05723909A patent/EP1722797A4/en not_active Withdrawn
- 2005-02-25 CN CNA2005800131929A patent/CN1964716A/zh active Pending
- 2005-02-25 AU AU2005216978A patent/AU2005216978A1/en not_active Abandoned
- 2005-02-25 MX MXPA06009701A patent/MXPA06009701A/es not_active Application Discontinuation
- 2005-02-25 CA CA002557547A patent/CA2557547A1/en not_active Abandoned
- 2005-02-25 EA EA200601558A patent/EA200601558A1/ru unknown
- 2005-02-25 WO PCT/US2005/006243 patent/WO2005082368A1/en active Application Filing
- 2005-02-25 KR KR1020067019577A patent/KR20060125909A/ko not_active Application Discontinuation
-
2006
- 2006-08-22 IL IL177650A patent/IL177650A0/en unknown
- 2006-09-21 ZA ZA200607913A patent/ZA200607913B/xx unknown
- 2006-09-25 NO NO20064328A patent/NO20064328L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL177650A0 (en) | 2006-12-31 |
ZA200607913B (en) | 2008-02-27 |
AU2005216978A1 (en) | 2005-09-09 |
KR20060125909A (ko) | 2006-12-06 |
JP2007527872A (ja) | 2007-10-04 |
EP1722797A1 (en) | 2006-11-22 |
US20050228007A1 (en) | 2005-10-13 |
EP2033645A1 (en) | 2009-03-11 |
WO2005082368A1 (en) | 2005-09-09 |
CA2557547A1 (en) | 2005-09-09 |
MXPA06009701A (es) | 2007-03-26 |
EP1722797A4 (en) | 2008-03-19 |
CN1964716A (zh) | 2007-05-16 |
BRPI0508233A (pt) | 2007-07-17 |
EA200601558A1 (ru) | 2007-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064328L (no) | Isoquinolinderivater og fremgangsmater for anvendelse derav | |
NO20074737L (no) | Isokinolinforbindelser og fremgangsmater for anvendelse derav | |
NO20064327L (no) | Tetracycliske laktamderivater og anvedelse derav | |
Bamishaiye et al. | Proximate and phytochemical composition of Moringa oleifera leaves at three stages of maturation | |
Wang et al. | Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by activating Nrf2 | |
Gracia-Sancho et al. | New cellular and molecular targets for the treatment of portal hypertension | |
Kelly et al. | Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase | |
WO2005009398A3 (en) | Tetracyclic benzamide derivatives and methods of use thereof | |
NO20071610L (no) | Immunogen sammensetning | |
WO2009099628A3 (en) | Compositions and methods for influencing recovery from strenuous physical activity | |
DK2155866T3 (da) | Modificerede phosphataser | |
NO20074412L (no) | Bruddresistente administrasjonsformer med forsinket frigiving | |
NZ715983A (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
BR112014005134A2 (pt) | composição farmacêutica de dissolução rápida | |
NO20083979L (no) | Farmasoytisk sammensetning omfattende oseltamivirfosfat | |
Naghshin et al. | Chronic intermittent hypoxia increases left ventricular contractility in C57BL/6J mice | |
Kaljusto et al. | Postconditioning in rats and mice | |
BRPI0402694A (pt) | Dispositivo para coleta de safra | |
BRPI0606191A2 (pt) | compostos de amino e carboxamido tetracìclicos e métodos do seu uso | |
Erer et al. | Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia–reperfusion injury in rats | |
Dabiri et al. | Effects of cannabis on cardiovascular system: the good, the bad, and the many unknowns | |
WO2007070355A3 (en) | Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes | |
Asher et al. | Factors predicting duration of delayed graft function in non-heart-beating donor kidney transplantation | |
Gokturk et al. | Long-term treatment with a beta-blocker timolol attenuates renal-damage in diabetic rats via enhancing kidney antioxidant-defense system | |
EA201071309A1 (ru) | Твердая фармацевтическая композиция |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |